A share price of CRISPR Therapeutics AG [CRSP] is currently trading at $44.43, up 2.87%. An important factor to consider is whether the stock is rising or falling in short-term value. The CRSP shares have gain 7.01% over the last week, with a monthly amount glided 14.87%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on February 14, 2025, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $99 from $60. Previously, TD Cowen upgraded its rating to Hold on February 12, 2025, and kept the price target unchanged to $35. On February 03, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $65 on the stock. Needham reiterated its Buy rating and decreased its price target to $84 on August 06, 2024. Rodman & Renshaw initiated its recommendation with a Buy and recommended $90 as its price target on August 02, 2024. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
CRISPR Therapeutics AG experienced fluctuations in its stock price throughout the past year between $30.04 and $63.68. Currently, Wall Street analysts expect the stock to reach $65 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $44.43 at the most recent close of the market. An investor can expect a potential return of 46.3% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
Trailing Twelve Months sales for CRISPR Therapeutics AG [NASDAQ:CRSP] were 37.67M which represents 71.63% growth. Gross Profit Margin for this corporation currently stands at -2.4% with Operating Profit Margin at -12.83%, Pretax Profit Margin comes in at -10.32%, and Net Profit Margin reading is -10.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.2 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.05 points at the first support level, and at 39.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.92, and for the 2nd resistance point, it is at 49.42.
Ratios To Look Out For
To put it in perspective, the Current Ratio for CRISPR Therapeutics AG [NASDAQ:CRSP] is 15.64. On the other hand, the Quick Ratio is 15.64, and the Cash Ratio is 1.97. Considering the valuation of this stock, the price to sales ratio is 101.86, the price to book ratio is 2.10.
Transactions by insiders
Recent insider trading involved Patel Naimish, Chief Medical Officer, that happened on May 29 ’25 when 3932.0 shares were sold. Chief Executive Officer, Kulkarni Samarth completed a deal on Mar 21 ’25 to sell 10031.0 shares. Meanwhile, Chief Operating Officer Bruno Julianne sold 1714.0 shares on Mar 21 ’25.
